Genovis expands its US presence and signs distribution agreement with Bulldog Bio Inc.
Genovis provides novel technical solutions for Transfection, RNAi, Imaging and Antibody Engineering for customers involved in sophisticated research in the pharmaceutical industry and academic research community.
For two years the fully owned subsidiary Genovis Inc. has consistently built sales channels in the US. During this period several distribution agreements have been entered, and Genovis has thus decided to close down its subsidiary and to work only through distributors and collaborators in the US market.
”This distribution agreement is an important step for Genovis as we expand into the North American market. The agreement broadens our presence and increases the exposure of our trademark. I am pleased with the opportunities this represents and I look forward to working with Bulldog Bio and their efficient and experienced team”, says Sarah Fredriksson, CEO Genovis AB.
Bulldog Bio is committed to growing the market share and revenue of its partners’ product lines in the US Life Science research community. Brand building, technical expertise and world-class support are the foundation of Bulldog Bio’s business model. The company employees have broad competence in Genovis’ business areas and pride themselves on efficient service and effective marketing.